EGFR and adenocarcinoma: The majority [62.2% (33/53)] of participating laboratories indicated that they routinely carry out reflex EGFR testing in non-squamous NSCLC, while 28.3% (15/53) carried out reflex testing in adenocarcinoma and 13.2% (7/53) in all histological subtypes, including squamous cell carcinoma (data not shown).